Explanipedia

The Current Landscape of Repurposed Drugs for Fungal Neglected Tropical Diseases Open

Tahsin Farid, Keyla C Tumas, Heather Stone, Mili Duggal · 2025

Wrangling Real-World Data: Optimizing Clinical Research Through Factor Selection with LASSO Regression Open

Kerry A. Howard, Wes Anderson, Jagdeep T. Podichetty, R. Bruce Gould, Danielle Boyce , et al. · 2025

Data-driven approaches to clinical research are necessary for understanding and effectively treating infectious diseases. However, challenges such as issues with data validity, lack of collaboration, and difficult-to-treat infectious disea…

Drug repurposing for rare: progress and opportunities for the rare disease community Open

Anneliene Hechtelt Jonker, Daniel O’Connor, Maria Cavaller-Bellaubi, Christine Fetro, Μαρία Γώγου , et al. · 2024

Repurposing is one of the key opportunities to address the unmet rare diseases therapeutic need. Based on cases of drug repurposing in small population conditions, and previous work in drug repurposing, we analyzed the most important lesso…

844. Landscape Analysis to Identify Effective Drug Repurposing Candidates for the Treatment of Implantation Mycoses: Comparison of World Health Organization Survey Treatment Data and Published Case Reports on CURE ID Open

Reema Charles, Barbara Milani, Daniel Argaw Dagne, B Ali, Heather Stone , et al. · 2023

Background Implantation mycoses are a group of fungi that gain access through cutaneous or mucosal wounds or by contact. The most widespread implantation mycosis is sporotrichosis. Chromoblastomycosis, eumycetoma, and coccidioidomycosis ar…

1402. The Landscape of Infections Caused by Rare Bacterial Pathogens Open

Tahsin Farid, Reema Charles, Keyla C Tumas, Heather Stone, Raghavendra Tirupathi · 2023

Background Rare infectious diseases (RIDs) are a significant source of morbidity and mortality1. Most lack approved treatments and it is difficult to perform comprehensive trials on therapeutic efficacy due to their sporadic nature and dis…

A metagenomic analysis for combination therapy of multiple classes of antibiotics on the prevention of the spread of antibiotic-resistant genes Open

Matthew J. Igo, Lei Xu, Ashok Krishna, Sharron Stewart, Lin Xu , et al. · 2023

Antibiotics used systemically to treat infections may have off-target effects on the gut microbiome, potentially resulting in the emergence of drug-resistant bacteria or selection of pathogenic species. These organisms may present a risk t…

The IRDiRC Drug Repurposing Guidebook: Creating an efficient and visible pathway for rare diseases Open

Anneliene Hechtelt Jonker, Daniel O’Connor, Michela Gabaldo, Simon Day, Martin de Kort , et al. · 2023

Drug repurposing is an exciting topic in the world of rare diseases, and it has often been suggested as a key approach for developing more therapies for the estimated 6000-8000 rare diseases. This strategy can be an attractive option becau…

Infezioni in Medicina Open

Shreya Das Adhikari, Souvik Chaudhuri, Carl Boodman, Mukund Gupta, Marco Schito , et al. · 2023

Fosfomycin has moderate clinical success in patients with non-urinary tract infections, especially when used with other antimicrobials. Due to the paucity of randomized controlled trials, fosfomycin's use should be limited to situations wh…

Evaluation of a Sequential Antibiotic Treatment Regimen of Ampicillin, Ciprofloxacin and Fosfomycin against Escherichia coli CFT073 in the Hollow Fiber Infection Model Compared with Simultaneous Combination Treatment Open

Ashok Krishna, Tesfalem Zere, Sabyasachy Mistry, Omnia A. Ismaiel, Heather Stone , et al. · 2022

Objective: Employ the hollow fiber infection model (HFIM) to study sequential antibiotic administration (ampicillin, ciprofloxacin and fosfomycin) using human pharmacokinetic profiles to measure changes in the rate of antibiotic resistance…

627. CURE ID as a Tool for Curating and Analyzing Drugs Used in COVID-19 Clinical Trials Open

Reema Charles, Parvesh Paul, Heather Stone, Serghei Gorobet, Belinda Nhundu , et al. · 2021

Background CURE ID is an internet-based data repository (https://cure.ncats.io/explore) developed collaboratively by FDA and NCATS/NIH. It is designed to capture real-world clinical outcome data to advance drug repurposing and to inform fu…

546. Capturing Clinician’s Experiences Repurposing Drugs to Inform Future Studies During COVID-19 Open

Mili Duggal, Heather Stone, Parvesh Paul, Reema Charles, Leonard Sacks , et al. · 2020

Background CURE ID is an internet-based repository developed collaboratively by FDA and NCATS/NIH, with the support of WHO and IDSA. It encourages clinicians globally to share novel uses of existing drugs for patients with difficult-to-tre…

1380. Safety of Repurposed Drugs for Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: An Analysis of Adverse Events Reported in the Literature Open

Heather Stone, Mili Duggal, Leonard Sacks, Mayurika Ghosh · 2019

Background Multi and extensively drug-resistant (MDR and XDR) tuberculosis (TB) remains a treatment challenge due to drug adverse events (AEs) and long regimens. Our aim was to identify AEs which resulted from repurposing drugs for MDR and…

Collaborative Use Repurposing Engine (CURE): FDA-NCATS/NIH Effort to Capture the Global Clinical Experience of Drug Repurposing to Facilitate Development of New Treatments for Neglected and Emerging Infectious Diseases Open

Heather Stone, Leonard Sacks, Rosemary Tiernan, Mili Duggal, Timothy Sheils , et al. · 2017

Background Repurposing approved products has proven a critical strategy to serve unmet medical needs. Historically, 40% of drugs approved for treatment of tropical diseases were repurposed, including albendazole for echinococcosis and neur…

Heather Stone YOU? Author Swipe